Equity
AKRO
Akero Therapeutics (AKRO)
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for AKRO to draw a line in its place.
Have Akero Therapeutics (AKRO) insiders bought or sold shares recently?
AKRO has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 9 December 2025.
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 09 Dec 2025 | Iwicki Mark T | Disposition to issuer | 221,705 | |
| 09 Dec 2025 | Harrison Seth Loring | Disposition to issuer | 347,762 | |
| 09 Dec 2025 | Henderson Jane | Disposition to issuer | 75,195 | |
| 09 Dec 2025 | Gangloff Scott A.Chief Technology Officer | Disposition to issuer | 322,451 | |
| 09 Dec 2025 | Graham G. Walmsley | Disposition to issuer | 1,317,398 | |
| 09 Dec 2025 | Cheng AndrewPresident and CEO | Disposition to issuer | 2,115,591 | |
| 09 Dec 2025 | Young JonathanChief Operating Officer | Disposition to issuer | 732,271 | |
| 09 Dec 2025 | White William RichardChief Financial Officer | Disposition to issuer | 689,753 | |
| 09 Dec 2025 | Lamy PatrickSee Remarks | Disposition to issuer | 242,555 | |
| 09 Dec 2025 | Yale CatrionaChief Development Officer | Disposition to issuer | 531,375 | |
| 09 Dec 2025 | Rolph TimothyChief Scientific Officer | Disposition to issuer | 659,089 | |
| 09 Dec 2025 | Judy Chou | Disposition to issuer | 50,398 |
Showing the 12 most recent of 16 compensation filings in this window. The figures above count all of them.
Which funds hold Akero Therapeutics (AKRO)?
0 of the 45 institutional funds we track reported a Akero Therapeutics position for the quarter ended 31 Dec 2025; the latest of those filings landed 17 Feb 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| AQR Capital Management | Exited | |||
| Baker Bros. Advisors | Exited | |||
| Bridgewater Associates | Exited | |||
| Citadel Advisors | Exited | |||
| D. E. Shaw & Co. | Exited | |||
| Marshall Wace | Exited | |||
| Millennium Management | Exited | |||
| Point72 Asset Management | Exited | |||
| Renaissance Technologies | Exited | |||
| Tudor Investment Corp | Exited |
Have members of Congress traded Akero Therapeutics (AKRO)?
The most recent congressional trade disclosed in Akero Therapeutics is a purchase by Sara Jacobs (house, CA), dated 08 Nov 2022.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 08 Nov 2022 | Sara Jacobshouse · Democrat–CA | Purchase | 1K USD–15K USD | 34 days |
Akero Therapeutics (AKRO): frequently asked questions
Have Akero Therapeutics insiders bought or sold shares recently?
No Akero Therapeutics insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 9 Dec 2025 (SEC Form 4). See Insiders
Which funds own Akero Therapeutics?
0 of the 45 funds we track reported a Akero Therapeutics position for the quarter ended 31 Dec 2025, per their SEC Form 13F filings. The largest reported positions were AQR Capital Management, Baker Bros. Advisors and Bridgewater Associates. See Funds
Have members of Congress traded Akero Therapeutics?
Yes. 1 trade in Akero Therapeutics appears in the congressional disclosures we hold: a purchase by Sara Jacobs (House, CA) dated 8 Nov 2022, filed 12 Dec 2022. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- House disclosuresU.S. House of Representatives financial disclosures